Panel Discussion: Walking the Therapeutic Tightrope Between Efficacy & Safety in B-Cell Targeted Therapies for Autoimmune Diseases vs Oncology

Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

• Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
• Addressing the risks associated at various level of depletion such as elevated BAFF
• Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion

Speakers:

Ricardo Grieshaber-Bouyer

Professor - Clinical Systems Immunology

Friedrich-Alexander- Universität Erlangen- Nürnberg

Chloe Slichter

Director – Discovery Biology

Kite Pharma

Min Bao

CMO

Kali Therapeutics